Results of EGM &Equity Issues

Oxford Biomedica PLC
17 April 2001

                              
 Not for release, publication or distribution in or into the
              United States, Canada, Australia,
              Japan or the Republic of Ireland
                              
                    OXFORD BIOMEDICA PLC
                    ('Oxford BioMedica')
                              
               Admission to the Official List
                              
          Results of the Placing and the Open Offer
                              
        Results of the Extraordinary General Meeting

On  12  March 2001, the Board of Oxford BioMedica  announced
that  it  had  applied to the UK Listing Authority  for  the
Company's  172,347,312 Existing Ordinary Shares, and  up  to
73,699,701  New Ordinary Shares to be issued pursuant  to  a
Placing  and  an Open Offer, to be admitted to the  Official
List  and for such shares to be admitted to trading  on  the
London Stock Exchange.

The  Board  of  Oxford  BioMedica  also  announced  that  it
proposed   to  raise  additional  funding  to  continue   to
strengthen  the  company  and  to  progress  its   candidate
products  to  a  stage  where they can generate  significant
revenues  for the Oxford BioMedica Group, through a  Placing
and an Open Offer.

By  3.00 p.m. on Monday, 9 April 2001, being the latest time
for  acceptance  and payment in full under the  Open  Offer,
acceptances  under  the  Open Offer  had  been  received  in
respect   of   5,277,814   new  Ordinary   Shares,   raising
£2,902,798.  Of the Offer Shares not taken up by  Qualifying
Shareholders, 4,704,545 have been placed by Beeson  Gregory,
as   agent  for  the  Company  at  55p  per  share,  raising
£2,587,500, before expenses.

The  Board is also raising approximately £27 million net  of
expenses  by means of the Placing of 54,550,000 new Ordinary
Shares  at 55p per share. The Placing was fully underwritten
by Rothschild and Beeson Gregory jointly.

All   resolutions  proposed  at  the  Extraordinary  General
Meeting  held  on Thursday, 12 April 2001,  were  passed  by
Oxford BioMedica Shareholders.

The  Company is expected to  be  admitted  to  the  Official 
List  today,  Tuesday, 17 April 2001, when dealings  in  the
Existing  Ordinary  Shares and the New Ordinary  Shares  are
expected to commence.

Commenting,  Alan  Kingsman,  Chief  Executive   of   Oxford
BioMedica, said:

'We  are  delighted with the outcome of the Placing and  the
Open Offer.  In a difficult climate for any company, we have
succeeded in completing our largest ever fund raising  which
will  allow  us  to expand our clinical trial  pipeline  and
intellectual property portfolio, further build on our record
of  strategic alliances and collaborations and establish our
presence  in the US with Oxford BioMedica Inc.   This  is  a
very exciting new phase for the Company, and we look forward
to keeping you informed of our progress going forward.'

For further information:

Oxford BioMedica plc                         [phone]
Alan Kingsman, Chief Executive

N M Rothschild & Sons Limited               [phone]
Tony Stuart

Beeson Gregory Limited                      [phone]
Nick Rodgers
Shaun Claydon

Merlin Financial                            [phone]
David Simonson
Melanie Toyne Sewell

HCC De Facto Group                          [phone]
Chris Gardner

Rothschild, which is regulated by The Securities and Futures
Authority  Limited,  is  acting  as  financial  adviser  and
sponsor  to   Oxford  BioMedica  in  connection   with   the
Admission,  the Placing and the Open Offer and no  one  else
and  will not be responsible to any person other than Oxford
BioMedica, for  providing  the  protections  afforded to its
customers  or  for  providing  advice  in  relation  to  the
Admission, the Placing and the Open Offer.

Beeson  Gregory,  which is regulated by The  Securities  and
Futures  Authority Limited, is acting as  broker  to  Oxford
BioMedica in connection  with  the  Admission,  the  Placing
and  the  Open  Offer  and  no one  else  and  will  not  be
responsible  to any person other than  Oxford  BioMedica, as
broker,  for  providing  the  protections  afforded  to  its
customers  or  for  providing  advice  in  relation  to  the
Admission, the Placing and the Open Offer.

This announcement is not an offer of securities for sale  in
the United States and the New Ordinary Shares have not been,
and   will  not  be,  registered  under  the  United  States
Securities Act of 1933 (as amended), nor under the  laws  of
any  state of the United States, and the relevant clearances
have  not  and  will  not  be  obtained  from  the  relevant
authorities in Canada, the Republic of Ireland, Australia or
Japan.  Accordingly, New Ordinary Shares may not be offered,
sold  or  delivered directly, or indirectly in or into  such
jurisdictions.